The Association between Antihypertensive Medication Use and Blood Pressure Is Influenced by Obesity
Authors:
Open Access
- 1 October 2018
- journal article
- research article
- Published by Wiley in Journal of Obesity
- Vol. 2018, 1-11
Abstract
Introduction. One in three US adults is living with obesity or hypertension, and more than 75% of hypertensive individuals are using antihypertensive medications. Therefore, it is important to examine blood pressure (BP) differences in populations that are using these medications with differing obesity status. Aim. We examined whether BP attained when using various antihypertensive medications varies amongst different body mass index (BMI) categories and whether antihypertensive medication use is associated with differences in other metabolic risk factors, independent of BMI. Methods. Adults with hypertension from the National Health and Nutrition Examination Survey (NHANES) from 1999 to 2014 were used (). Linear regression analyses were used to examine the main effects and interaction between antihypertensive use and BMI. Results. In general, users of antihypertensive medications had lower BP than those not taking BP medications (NoBPMed) (), whereby in women, the differences in systolic BP between angiotensin-converting-enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) users and NoBPMed were greater in those with obesity (ACE inhibitors: −14 ± 1 mmHg; ARB: −16 ± 1 mmHg) compared to normal weight individuals (ACE inhibitors: −9 ± 1 mmHg; ARB: −11 ± 1 mmHg) (). Diastolic BP differences between women ARB users and NoBPMed were also greatest in obesity (−5 ± 1 mmHg) () whilst there were no differences in normal weight individuals (−1 ± 1 mmHg) (). Furthermore, glucose levels and waist circumference in women were higher in those using ACE inhibitors compared to diuretics (). Conclusion. ACE inhibitors and ARBs may be associated with more beneficial BP profiles in women with obesity, with no obesity-related BP differences for antihypertensive medication in men. However, there could be potential cardiometabolic effects for some antihypertensive medications that should be explored further.
Keywords
Funding Information
- Canadian Institutes of Health Research (131594)
This publication has 56 references indexed in Scilit:
- Sex and gender differences in control of blood pressureClinical Science, 2013
- Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trialThe Lancet, 2013
- Weight loss for reduction of proteinuria in diabetic nephropathy: Comparison with angiotensin-converting enzyme inhibitor therapyIndian Journal of Nephrology, 2013
- The renin–angiotensin–aldosterone system and glucose homeostasisTrends in Pharmacological Sciences, 2011
- Role of adipose tissue renin–angiotensin system in metabolic and inflammatory diseases associated with obesityKidney International, 2011
- Disparity in Physician Perception of Patients' Adherence to Medications by Obesity StatusObesity, 2010
- Genetic Basis of HypertensionHypertension, 2006
- Change in β1-adrenergic receptor protein concentration in adipose tissue correlates with diet-induced weight lossClinical Science, 2005
- Effects of Obesity on PharmacokineticsClinical Pharmacokinetics, 2000
- Impact of the menopause on the epidemiology and risk factors of coronary artery heart disease in womenExperimental Gerontology, 1994